1ml of Semaglutide: What That Measurement Really Tells You

The misconception: treating 1ml as though it equals one dose of semaglutide

The most common reason this query appears is that people have come across vials or syringes described in millilitres, usually through social media sellers or grey-market listings. The assumption is that 1ml of liquid equals one weekly dose. It does not, and that conflation is genuinely risky.

Milligrams measure mass; millilitres measure volume. The relationship between the two depends on the concentration of the solution, which varies between products and manufacturers. A 1ml vial of one preparation might contain 2mg of semaglutide; a different vial at a different concentration might contain 5mg. Without knowing the exact concentration, a volume measurement tells you almost nothing about how much active medicine you are actually taking.

The MHRA has been explicit about this. Unlicensed compounded semaglutide (often sold in vials and drawn into syringes by the patient) has been found in circulation without reliable quality controls, meaning the stated concentration may not match what is actually in the vial. Some seizures have involved products with no active ingredient at all. The regulator's guidance on reporting suspect medicines is worth bookmarking if you have encountered this kind of listing.

Licensed Wegovy pens sidestep this entirely. Each pen is pre-filled and pre-set: you dial nothing, measure nothing, and draw nothing. The device delivers a fixed, verified milligram dose in a controlled injected volume. That is the design feature that removes the concentration calculation from the patient's hands.

What the licensed Wegovy dose ladder actually looks like

The UK-licensed Wegovy injection schedule starts at 0.25mg per week, which is a low starting point chosen to help the body adjust rather than to produce significant weight loss immediately. After roughly four weeks, a prescriber typically moves a patient up to 0.5mg, then 1.0mg, then 1.7mg, and eventually to 2.4mg as the standard maintenance dose. In January 2026, the MHRA approved a 7.2mg maintenance option, subsequently available as a dedicated single-dose pen, meaning the top of the licensed ladder has now risen considerably for some patients.

None of these steps are self-directed. The timing, and whether to continue at any given dose, is a clinical decision based on tolerability and response. You can read more about how often semaglutide is injected and what drives those decisions clinically.

The STEP 1 trial, published in the New England Journal of Medicine, reported an average body-weight reduction of around 15% over 68 weeks at 2.4mg alongside lifestyle changes in adults with obesity. That figure comes from a licensed, concentration-verified product, not from a vial measured in millilitres. The distinction is not pedantic; it reflects genuine differences in what patients actually received.

If cost is part of what's driving interest in unlicensed alternatives, the Wegovy cost page sets out what private treatment realistically involves and what a legitimate price typically covers.

Why vial-and-syringe semaglutide is not the same thing

Compounded semaglutide in vials is not licensed by the MHRA for weight management. It is not the same product as Wegovy. It does not go through the same manufacturing quality checks, and the concentration printed on the label is not subject to the same regulatory verification. That matters for two reasons beyond the obvious safety concerns.

First, any dose calculation you make from a vial (converting a volume to an assumed milligram amount) rests on a concentration figure you have no independent way to verify. Second, if something goes wrong, neither the prescriber nor the pharmacist can adjust or reverse a self-drawn dose with the confidence they could with a licensed pen.

Our semaglutide overview covers the licensed product in full, including what the pre-filled pen format means in practice. For a closer look at how Wegovy sits within the broader picture of licensed weight-loss treatment in the UK, the Wegovy page is a good starting point.

It is also worth knowing that Ozempic, which is also semaglutide, is licensed in the UK for type 2 diabetes, not for weight management. The NHS's semaglutide medicines page explains the distinction clearly.

How semaglutide is legitimately prescribed in the UK

Wegovy is a prescription-only medicine under UK law. Getting it legally requires a consultation with a qualified prescriber who can confirm it's appropriate for you, checking your BMI, medical history, any medicines you're already taking, and whether the dose schedule suits your circumstances. There is no shortcut that preserves the safety of that process.

A question our prescribers hear regularly is whether someone who found semaglutide described in millilitres online is in the right place. They are not. The licensed route starts with a consultation, not a conversion calculator.

If you want to understand more about the full range of weight-loss treatments available through a regulated UK pharmacy, the weight-loss treatments overview is a clear starting point. Specific questions about the 1mg step of the Wegovy dose schedule can be found on the semaglutide 1mg page and the semaglutide 2mg page for the next stage. The Wegovy 1ml guide also addresses the volume-measurement question from a device perspective.

Speak to our prescribers if you are trying to make sense of what you've read online, a free consultation is the clearest way to get a straight answer about whether semaglutide is appropriate for you, and at what dose.